GlassScriptPhysician profile
Mark H Johnston
NPI 1003898131
$3,034.57
in general payments reported to CMS, 2019-2025
20 companies · $578 in 2025
The $578 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $87.74 · 2021: $126 · 2022: $384 · 2023: $822 · 2024: $690 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.24 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $302.28 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $203.80 | 2021-2023 | Zeposia |
| Genzyme Corporation | $199.46 | 2022-2025 | |
| Janssen Biotech, INC. | $159.19 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.75 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $135.12 | 2023-2025 | Ibsrela |
| Pfizer INC. | $125.82 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $102.68 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $89.59 | 2024-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $67.32 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $61.06 | 2022-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $44.98 | 2019-2022 | |
| Shionogi INC | $37.92 | 2019 | |
| Abiomed | $36.82 | 2024 | Impella |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.14 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $23.56 | 2022 | |
| Fresenius Kabi USA, LLC | $19.68 | 2023 | |
| Novo Nordisk INC | $19.57 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $18.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.